share_log

Alzamend Neuro | 10-K: FY2024 Annual Report

Alzamend Neuro | 10-K: FY2024 Annual Report

Alzamend Neuro | 10-K：2024财年年报
美股SEC公告 ·  2024/07/31 10:20

Moomoo AI 已提取核心信息

Alzamend Neuro, Inc. reported financial results for the fiscal year ended April 30, 2024. The clinical-stage biopharmaceutical company focused on Alzheimer's and other neurodegenerative disorders recorded no revenue, consistent with the previous year. Net loss narrowed to $9.9 million from $14.9 million in FY2023, primarily due to reduced operating expenses.Research and development expenses decreased to $6.5 million from $7.4 million, while general and administrative costs fell significantly to $3.5 million from $7.4 million. The company ended the fiscal year with $376,000 in cash, down from $5.1 million at the end of FY2023. Alzamend raised $3.7 million through financing activities during the year, including the issuance of preferred stock and warrants.Alzamend continued to advance its lead candidates AL001 and ALZN002 through clinical trials. The company completed a Phase IIA study for AL001 and initiated a Phase I/IIA trial for ALZN002. Management expressed confidence in the potential of these therapies but acknowledged the need for substantial additional funding to complete development and commercialization efforts.
Alzamend Neuro, Inc. reported financial results for the fiscal year ended April 30, 2024. The clinical-stage biopharmaceutical company focused on Alzheimer's and other neurodegenerative disorders recorded no revenue, consistent with the previous year. Net loss narrowed to $9.9 million from $14.9 million in FY2023, primarily due to reduced operating expenses.Research and development expenses decreased to $6.5 million from $7.4 million, while general and administrative costs fell significantly to $3.5 million from $7.4 million. The company ended the fiscal year with $376,000 in cash, down from $5.1 million at the end of FY2023. Alzamend raised $3.7 million through financing activities during the year, including the issuance of preferred stock and warrants.Alzamend continued to advance its lead candidates AL001 and ALZN002 through clinical trials. The company completed a Phase IIA study for AL001 and initiated a Phase I/IIA trial for ALZN002. Management expressed confidence in the potential of these therapies but acknowledged the need for substantial additional funding to complete development and commercialization efforts.
Alzamend Neuro, Inc. 报告了截至2024年4月30日的财政年度财务结果。这家专注于阿尔茨海默病和其他神经退行性疾病的临床阶段生物制药公司未记录营业收入，与前一年保持一致。净亏损缩小至990万美元，较2023财年的1490万美元有所减少，主要由于营业费用的降低。研发费用从740万美元降至650万美元，而一般和行政费用则显著下降，从740万美元降至350万美元。公司在财政年度结束时持有现金376,000美元，低于2023财年末的510万美元。Alzamend 通过融资活动共筹集了370万美元，包括优先股和Warrants的发行。Alzamend 继续推进其主要候选药物AL001和ALZN002的临床试验。公司完成了AL001的IIA期研究，并启动了ALZN002的I/IIA期试验。管理层对这些疗法的潜力表示信恳智能，但承认需要大量额外资金来完成开发和商业化工作。
Alzamend Neuro, Inc. 报告了截至2024年4月30日的财政年度财务结果。这家专注于阿尔茨海默病和其他神经退行性疾病的临床阶段生物制药公司未记录营业收入，与前一年保持一致。净亏损缩小至990万美元，较2023财年的1490万美元有所减少，主要由于营业费用的降低。研发费用从740万美元降至650万美元，而一般和行政费用则显著下降，从740万美元降至350万美元。公司在财政年度结束时持有现金376,000美元，低于2023财年末的510万美元。Alzamend 通过融资活动共筹集了370万美元，包括优先股和Warrants的发行。Alzamend 继续推进其主要候选药物AL001和ALZN002的临床试验。公司完成了AL001的IIA期研究，并启动了ALZN002的I/IIA期试验。管理层对这些疗法的潜力表示信恳智能，但承认需要大量额外资金来完成开发和商业化工作。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

独立文件8  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间